Organogenesis Secures FDA Review For ReNu In Knee Osteoarthritis
(RTTNews) – Organogenesis Holdings Inc. (ORGO) announced that the U.S. FDA has accepted its Biologics License Application (BLA) for ReNu, a cryopreserved amniotic suspension allograft designed to manage pain in patients with symptomatic knee osteoarthritis. Knee osteoarthritis (OA) is a degenerative disease affecting nearly 31 million Americans, with projections rising to more than 34 million…